| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) financing activities | 168,341,137 | -347,829 |
| Effect of exchange rate changes on cash and cash equivalents | 184,364 | 221,901 |
| Net increase (decrease) in cash and cash equivalents | 20,526,742 | -5,205,749 |
| Cash and cash equivalents at beginning of period | 8,897,966 | - |
| Cash and cash equivalents at end of period | 29,424,708 | - |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)